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Metaheuristic search algorithms are used to develop new protocols for optimal intravenous
insulin infusion rate recommendations in scenarios involving hospital in-patients with Type 1
Diabetes. Two metaheuristic search algorithms are used, namely, Particle Swarm Optimization
and Covariance Matrix Adaption Evolution Strategy. The Glucose Regulation for Intensive
Care Patients (GRIP) serves as the starting point of the optimization process. We base our
experiments on a methodology in the literature to evaluate the favorability of insulin protocols,
with a dataset of blood glucose level/insulin infusion rate time series records from 16 patients
obtained from the Waikato District Health Board. New and signi¯cantly better insulin infusion
strategies than GRIP are discovered from the data through metaheuristic search. The newly
discovered strategies are further validated and show good performance against various com-
petitive benchmarks using a virtual patient simulator.
Keywords: Metaheuristic search; continuous optimisation; insulin infusion protocol; simulated
validation.
1. Introduction
Diabetes is a fast-growing global problem.1 It is caused by the body's inability to
produce insulin or due to body's resistance to insulin. Insulin is a hormone produced
by the pancreatic islets and it promotes the absorption of glucose from blood into
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cells. Patients admitted to our local hospital due to diabetes are subjected to con-
tinuous intravenous insulin infusion therapy. The goal of such therapy is to keep the
blood glucose levels of the patient in a de¯ned normal range (usually 6–10mmol/L).
This goal is achieved by adjusting the insulin infusion rate at approximately hourly
intervals in order to administer an appropriate amount of insulin throughout the
treatment. Each time, the infusion rate is either adjusted upwards to decrease the
risk of hyperglycemia, de¯ned as glucose levels being too high, or downwards to
minimize the risk of hypoglycemia, de¯ned as glucose levels being too low. Infusion
rate adjustments are generally carried out by nurses, who refer to a paper-based
protocol which includes sets of instructions and a lookup table to determine the
appropriate insulin infusion rate measured in units/h (U/h), where one unit of insulin
is de¯ned as the \biological equivalent" of 34:7g pure crystalline insulin. The protocol
also identi¯es scenarios where a doctor needs to be called to take over immediate care of
the patient (e.g. when the patient su®ers from severe hypoglycemia).
The research question that our research aims to explore is how to devise new
protocols for calculating the optimal insulin infusion rate for these patients in a
mathematically consistent way, and how to evaluate such protocols. There are
various ways of approaching the problem. In our research, metaheuristic search
algorithms are used in conjunction with insulin therapy data obtained from the local
hospital. The data come in the form of a time series of blood glucose levels/insulin
infusion rates for each patient's therapy session. The idea is to discover a protocol
that would have performed better than the current protocol with respect to the
historical data, if the protocol being tested had been applied in the same situation.
The Glucose Regulation for Intensive Care Patients (GRIP)2 serves as the base
framework for the metaheuristic search. The objective of the metaheuristic search is
augmented with a methodology in the literature for evaluating new insulin infusion
protocols based on historical data.3 GRIP utilizes a simple linear formula that can be
applied to data to calculate insulin infusion rate adjustments at any point of an
insulin therapy session whenever such adjustments are needed. GRIP requires as its
input the blood glucose and insulin infusion data during the past four hours of the
therapy.
The resulting protocols obtained from the metaheuristic search are validated
using Simglucose,4 which is a reimplementation of the FDA-approved Type 1 UVA/
Padova Simulator.4 Simglucose simulates a model of glucose and insulin which
represents a patient with Type 1 Diabetes. We use an adapted version of Simglucose
to evaluate intravenous insulin protocols in our research.
The novel contribution of our research is twofold. First, it shows that meta-
heuristic search algorithms can be used to optimize the parameters of GRIP, thus
improving and adopting the strategy with respect to the historical data. Second,
newly discovered strategies can be validated using simulated virtual patients, who
have never been exposed to the optimization process, and exhibit better performance
than both GRIP, which is the base of the optimization, and the current local hospital
practice, which is the historical protocol used to produce the data for optimization.







































































































This paper extends the paper entitled \Metaheuristics for Discovering Favorable
Continuous Intravenous Insulin Rate Protocols from Historical Patient Data".5 The
novel contribution of this paper over Ref. 5 is that Simglucose is used to verify
optimization results by applying the resulting protocols to virtual patients. This
paper shows how to use a patient simulator to fairly evaluate protocols optimized
using real-world patient data, which Ref. 5 does not. Additionally, this paper
includes more detail than Ref. 5, e.g. more detailed illustration of optimization
results and more comprehensive background on insulin infusion protocols.
2. Background
This section covers the background knowledge of our research, including various
insulin infusion protocols, metaheuristic search algorithms and Simglucose.
2.1. Existing insulin infusion protocols
In the literature, there are both algorithms developed for in-patients and ones de-
veloped for patients in Intensive Care Units. Although our research aims to develop
and optimize algorithm-based insulin infusion protocols for in-patients instead of
ICU patients, the ICU-based insulin infusion protocols provide nice comparison and
some of them can act as starting points for AI optimization.
Table 1 compares the protocols investigated during our research, in terms of the
amount of historical data used, the core form of a protocol, and the inner hidden
state of a protocol. The protocols are discussed in detail in the following subsections.
It should be noted that the units for blood glucose levels may di®er in di®erent
protocols, as some protocols use mmol/L while the others use mg/dL. This is heavily
dependent on the protocol's original country, because countries such as the United
States use mg/dL for blood glucose measurements, while the rest of the countries use
mmol/L, including New Zealand. The units of the protocols are kept as they are in
the original publications, and conversion is relatively easy as 1mmol/L of blood
glucose is equivalent to 18mg/dL of blood glucose.
2.1.1. Local DHB practice
At the local hospital, the nurses use a tabular and textual protocol (shown in Fig. 1
to assist in making intravenous insulin infusion rate decisions, and the protocol's
Table 1. Comparison of the protocols studied.
Max history utilized Core form Inner state
Waikato DHB 1h Instructions Infusion scale
GRIP 4 h Formula None
Glucommander 1 h Formula Multiplier
Glucosafe Cumulative from Start Formula Model parameters
Sigmoidal 8 h Instructions Infusion scale







































































































table is visualized in Fig. 2. The protocol should be referred to approximately each
hour, which means that insulin infusion rate decisions are made hourly.
The table in the protocol represents a function which takes a patient's blood
glucose level and an infusion rate scale as arguments and returns its recommended
insulin infusion rate. The scales represent di®erent amounts of insulin recommended
Fig. 1. The insulin infusion rate recommendation protocol currently in use at the Waikato District
Health Board, New Zealand. The protocol is in the form of an insulin infusion rate table and text
instructions.







































































































at each same blood glucose range, with the lower scales such as Scale A recom-
mending less insulin while the higher scales such as Scale E recommending more
insulin. The scales are needed as di®erent patients have di®erent physical conditions,
which make them require di®erent amounts of insulin when their blood glucose levels
fall in the the same range. For example, a lower-weighted patient generally requires
less insulin than a higher-weighted patient when they have the same blood glucose
level. In fact, there are many factors that in°uence a patient's requirement of insulin,
and most of them are not as easily identi¯ed or quanti¯ed as body weight, e.g. liver
function, kidney function, insulin sensitivity.
The textual instructions help determine and adjust the insulin infusion rate scale
for a patient. The initial scale is determined by a patient's physical condition and
medical history, with Scale B as the default scale for most patients, Scale A for thin
and/or insulin sensitive individuals and Scale C for insulin insensitive patients, while
Scale D and Scale E are generally not used as the initial scale and are only used when
Scale C proves to be insu±cient for a patient, i.e. when Scale C cannot keep the
patient's blood glucose level from rising above the normal range and therefore fails to
minimize the hyperglycemia risk.
An adjustment of infusion scale may occur if the current scale appear to be either
insu±cient or excessive for a patient. The ideal blood glucose range is speci¯ed
according to the patient's condition by the medical sta®, and this ideal range plays
an important role in determining the insu±ciency and excessiveness of an infusion
scale. In most scenarios for in-patients at the local hospital, an ideal range of 6–
10mmol/L is selected, which is higher than the 4–8 mmol/L range more commonly
seen in ICU settings, largely because the risk of hypoglycemia is usually more sig-
ni¯cant than the risk of hyperglycemia for in-patients who are already receiving
insulin intravenously.
A higher scale is adopted in the event of insu±cient insulin, with the insu±ciency
signi¯ed by blood glucose levels above the ideal range and not decreasing at a
satisfactory rate, i.e. decreasing by less than 1mmol/L since last hour or increasing.
Fig. 2. Visualization of the Waikato DHB protocol.







































































































On the other hand, a lower scale is adopted when insulin appears excessive, which is
signi¯ed by blood glucose levels below the ideal range or decreasing at an alarming
rate, i.e. decreasing by more than 4mmol/L since last hour.
It should be mentioned that the protocol recommends one unit of insulin bolus for
every 10 grams of carbohydrate consumed by the patient. However, not all protocols
take carbohydrate consumption into account as patients do not eat when some
protocols are in use, e.g. ICU protocols generally do not consider food intakes as
patients do not eat in intensive care. The boluses are discarded in the continuous
optimization process.
2.1.2. Glucose regulation for intensive care patients
GRIP2 is an algorithm-based protocol for calculating suitable intravenous insulin
infusion rate adjustments, originally intended for patients in ICU. In our research,
GRIP is utilized in a more general non-ICU setting in which any in-patient in need of
intravenous insulin infusion must be treated.
In GRIP, the recommended change in insulin infusion rate is determined by the
mean insulin infusion rate of the last four hours (I4 h), the current blood glucose
level (G0), the target blood glucose level (Gtarget, set to 6.5 in GRIP), and the change
in blood glucose level in the last four hours (4 hG). The blood glucose levels are
measured in mmol/L. If there is less than four hour's worth of data, e.g. the infusion
has just started, the infusion rate can be assumed to be zero before the starting point
and the blood glucose level four hours ago can be assumed to be equal to the earliest
measurement, and the output can then be calculated based on these assumptions.
GRIP's output is the recommended insulin infusion rate change (I) measured in U/
h. This is primarily a recommendation for medical sta® which may be overruled at
any time according to medical judgement. The GRIP formula is shown in Eq. (1).
I ¼ ð1þ 0:25 I4 hÞ  ð0:2ðG0 GtargetÞ þ 0:34 hGÞ: ð1Þ
GRIP is essentially a linear combination of four input variables, i.e. I4 h , G0,
Gtarget and 4 hG, with Gtarget usually set to a constant in each session of intravenous
insulin infusion therapy. In practice, further constraints are usually added to GRIPs
recommendation, for example rounding large positive values of I down to 1.5U/h
and rounding large recommended infusion rates down to 10U/h.2 In our experiments
these constraints are treated as optional \post processing" of the recommendations
that are speci¯c to the hospital itself and for optimization purposes the focus is solely
on the formula given in Eq. (1).
2.1.3. Other protocols
Glucommander is another simple and e®ective algorithm-based protocol.6 It can be
presented as a set of linear models of the blood glucose level, each having a di®erent
slope, called a multiplier in the context of the protocol. The current multiplier is
calculated using a function of the previous multiplier, the previous blood glucose
level and the current blood glucose level. The recommended insulin infusion rate is







































































































computed as the product of the current multiplier and the current blood glucose level
o®set by a constant. Lack of real-world data collected from Glucommander makes it
hard to be benchmarked against other protocols using known methods,3 as it would
be hard to reverse-engineer the multiplier at each recommendation.
Glucosafe is one of the more sophisticated protocols available.7 Glucosafe main-
tains a virtual model of the patient, i.e. modeling the state of the blood, the organs,
etc., in order to calculate the optimal insulin infusion rate based on the virtual
patient model. The sophistication of the protocol makes it not as good a candidate
for AI optimization techniques used in our experiments.
According to the literature, some hospitals utilize an insulin infusion rate rec-
ommendation protocol, the core of which is a sigmoidal function of the blood glucose
level.8,9 The sigmoidal protocol can be translated into a tabular protocol with textual
instructions that is very similar to the protocol used at the Waikato DHB, with the
blood glucose levels divided into ranges, the insulin infusion rate recommendations
rounded to one decimal place, its various multipliers represented as a series of in-
fusion scales, and the infusion rate scale in use adjusted by a set of textual
instructions. Its simplicity, as well as its similarity to the Waikato DHB protocol,
makes it an excellent protocol for comparison purposes during the validation process
of the algorithmic protocols produced by continuous optimization.
2.2. Metaheuristics for continuous optimization
A continuous optimization problem is an optimization problem where the variables
to be optimized are numeric, as opposed to discrete. The constants in an insulin
infusion rate calculation protocol are all real numbers, which means continuous
optimization algorithms are suitable for optimization of such protocols. The DEAP
framework is used to facilitate our continuous optimization experiments.10 Two
algorithms are used, i.e. Particle Swarm Optimization (namely, a speci¯c type of
PSO called Constriction Coe±cient Particle Swarm Optimization)11 and Covariance
Matrix Adaption Evolution Strategy (CMA-ES).12
PSO explores the search space using a population of particles, and in each iter-
ation the velocity of each particle is adjusted according to the known global and
individual optimums in the search space. Bonyadi and Michalewicz11 pointed out
that the original PSO algorithm may result in in¯nite velocity of its particles, causing
the particles to leave the reasonable search space. To prevent this behavior, they
presented a variant of the PSO formula in their review, named Constriction
Coe±cient Particle Swarm Optimization (CCPSO), which is the version we used.
CMA-ES explores the search space by randomly generating a population of
potential solutions per iteration based on an evolving distribution, composed of a
mean, a covariance matrix and a set of standard deviations along the axes.12 The
mean and the covariance matrix are derived from the best individuals in the popu-
lation. The step size of the optimization, i.e. the set of standard deviations, is con-
trolled by how much the directions of the steps di®er.








































































































Simglucose is a python implementation of the FDA-approved UVa/Padova Simu-
lator (2008 version)4 for research purpose only. It is implemented by Jinyu Xie. The
online version is Simglucose v0.2.1 (2018). Source: Ref. 14, accessed on 14/01/2020.
Simglucose is able to simulate thirty virtual patients with Type 1 Diabetes, in-
cluding 10 adults, 10 adolescents and 10 children. This is a valuable resource to our
experiments as it can be used to verify the performance of the insulin infusion rate
recommendation protocols produced by the continuous optimization experiments.
The virtual model of Simglucose is depicted in Fig. 3. Simglucose is designed to
evaluate insulin administration protocols used by an Arti¯cial Pancreas (AP), which
measures blood glucose levels and administers insulin subcutaneously, as opposed to
the intravenous treatment received by hospital in-patients. The AP is a device that is
carried by a patient with Diabetes, constantly monitoring the patient's glucose level
and administering insulin in order to keep the patient's glucose level stable and in
range. The AP is very similar in concept to the Arti¯cial Cardiac Pacemaker which is
carried by patients with heart problems and regulates a patient's heart functions,
while the AP regulates a patient's glucose–insulin balance. Simglucose simulates a
virtual patient's blood glucose level, plasma insulin concentration, and the interac-
tion between glucose and insulin, in addition to the relation between the subcuta-
neous system and the plasma balance.
In order to adapt the Simglucose system to simulate a hospital in-patient's in-
travenous insulin infusion treatment, where insulin is infused directly into the blood
and the blood glucose level is measured from ¯ngerstick blood, certain simulation
components need to be replaced. As subcutaneous glucose levels are determined by
blood glucose levels, the simulated blood glucose levels can be directly read as
Source: Ref. 13.
Fig. 3. The glucose–insulin model simulated by Simglucose for evaluating the performance an Arti¯cial
Pancreas insulin administration protocol.







































































































measurements obtained from ¯ngerstick blood. In the same vein, as insulin admin-
istered subcutaneously gets transferred into blood plasma, the transfer mechanism
can be replaced with a protocol's recommended insulin infusion rate so that intra-
venous insulin therapy can be simulated. The modi¯ed system is crosschecked with a
separate publication on intravenous insulin pharmacokinetics15 and the modi¯ed
system con¯gurations are con¯rmed to be valid.
3. Data Collection
The dataset used in our research was collected from the Waikato District Health
Board, New Zealand. The original data was in paper form, which was recorded by
nurses during the intravenous insulin infusion therapy sessions of hospital in-
patients.
Data of 16 intravenous insulin infusion therapy sessions were collected, and these
therapy sessions were received by 13 in-patients at the local hospital, three of whom
received two therapy sessions each during di®erent hospital admissions. In our
experiments, all the 16 therapy sessions are treated as from di®erent independent
patients to avoid unnecessary complexity and produce a protocol that can make
reasonable insulin infusion rate recommendations without any prior knowledge on
the patient.
The data of each patient are in the form of a time series, where each time point
stands for an insulin infusion rate adjustment and includes the following attributes:
. the date (DD/MM/YY),
. the time (hh:mm),
. the blood glucose levels measurement (mmol/L),
. the change in the blood glucose levels measurement since the last measurement
(mmol/L),
. the insulin infusion scale used by the nurse when referring to the insulin infusion
table,
. the insulin infusion rate decision (units/h) and
. the IV °uids and rate.
Some of the patients received insulin boluses in tandem with the intravenous insulin
infusion. The type, dosage and time of each insulin bolus was obtained alongside the
time series. However, the boluses are not taken into account during the continuous
optimization process to ¯nd a competitive recommendation protocol, and the reasons
are as follows:
(1) GRIP serves as the starting point of the optimization, and GRIP does not utilize
any insulin bolus, with the only insulin intakes being intravenous insulin infu-
sion. This is presumably due to GRIP being designed as an ICU protocol, while
the dataset for our experiments is collected from hospital in-patients. In addition,
the creators of GRIP believed that insulin boluses may intensify an e®ect called







































































































insulin saturation.2 Insulin saturation refers to the phenomenon where excessive
insulin in a patient's plasma cannot be utilized by it receptors immediately, and
may lead to increased hypoglycemia risks later on.16
(2) At the local hospital, the reason for an insulin bolus is usually to counteract a
recent carbohydrate intake, as it raises the blood glucose level temporarily.
However, food intake data was not collected from the hospital archive, and is
thus unavailable at the time of the optimization experiments. An additional
point is that the food intake data may not be bene¯cial to the optimization
nevertheless, as the e®ect of each carbohydrate intake on the blood glucose level
is hard to quantify and will only make the optimization process harder to fa-
cilitate and potentially less accurate. Also, the starting point of optimization,
GRIP, does not consider either carbohydrate intakes or boluses. Therefore, there
is hardly a justi¯able way of introducing carbohydrate in°uence.
According to the reasons above, it was decided that a reasonable course of action
would be to optimize GRIP without considering either carbohydrate intakes or bo-
luses, and the resulting protocol should run in tandem with a heuristic for insulin
boluses, e.g. bolus ðunitsÞ ¼ carbohydrate ðgramsÞ10 which is the current practice at the
local hospital, if carbohydrate intakes are present.
The IV °uid was disregarded as well, because its e®ect, more speci¯cally the e®ect
of the dextrose in it on the blood glucose level, is hard to quantify. Another practical
reason is that this data is not present on every sheet of written data and the amount
of missing data is signi¯cant. It was deemed best to assume that the rules for IV °uid
are similar enough in the scenarios of both GRIP and the local hospital.
Statistical analysis is performed on the data. There are 462 data points in the
entire dataset, with each data point representing an insulin infusion rate adjustment.
Fig. 4. Blood glucose status of each patient.







































































































The median number of adjustments per patient is 23, with the maximum number of
adjustments being 88 and the minimum number being 7.
Figure 4 shows the blood glucose status of each patient during their insulin in-
fusion session, i.e. the percentage of time with the patient's blood glucose level in the
normal range, as well as above and below the normal range. On average, the patients'
blood glucose levels are in the normal range for approximately 50% of the time, and it
is believed that there is room for improvement, which our research aims to achieve.
4. Method
This section covers the methodology of our research, including the favorability
evaluation method, di®erent optimization strategies, our approach to optimization
and the veri¯cation process.
4.1. Evaluation framework
Wong et al.3 proposed a methodology for evaluating algorithm-based insulin infusion
rate recommendation protocols against certain historical practice, which is usually
carried out using an algorithm-based protocol as well. The fundamental idea is to
estimate the insulin infusion rate that would have been recommended by the protocol
to be evaluated (e.g. GRIP), and how each of these hypothetical recommendations
compares to each of the corresponding actual recommendations made by the protocol
used in the historical practice (e.g. the method currently in use at the local hospital).
Historical data from a set of di®erent patients over the course of their insulin
infusion treatment are needed in order to facilitate the comparison. Ideally, each
patient should have at least 12 hours' worth of data. Each patient's dataset must
consist of a pair of time series, with one measuring the patient's blood glucose level at
each infusion rate decision (i.e. at each time point), and the other recording the
continuous insulin infusion rate at each of these decision points. Figure 5 depicts the
insulin infusion treatment of one such patient. The time points are separated by
approximately one hour in our data, which is consistent with the common intrave-
nous insulin therapy practice of approximately hourly adjustments.
Based on the historical data, the algorithmic protocol to be evaluated is invoked,
for each patient and each point in time, to calculate the insulin infusion rate that it
would have recommended, had it been used at that point, given the past blood
glucose levels and the amount of insulin already administered at the previous time
points of the same insulin therapy session. Due to di®erent algorithms being used in
the historical practice and the protocol to be evaluated, the recommendations they
make are most likely to di®er. This is the key point of the evaluation.
In order to assess whether the recommendation made by the protocol to be
evaluated is potentially better than that of the historical practice at a time t, the
blood glucose level at the next decision point in the time series (i.e. at tþ 60minutes)
needs to be examined. Essentially, if the future blood glucose level is above the
normal range, then the higher insulin infusion rate recommendation is to be







































































































preferred, and consequently, as is the algorithmic protocol that would have made
that recommendation. In other words, an above-range blood glucose level at the next
time point indicates that the amount of insulin administered in the historical practice
was insu±cient to minimize hyperglycemia risk, and an algorithm that would have
recommended a higher infusion rate could have performed better in keeping the
blood glucose level in range. Conversely, if the future blood glucose level is below
the normal range, then an algorithm recommending a lower insulin infusion rate is to
be preferred as this would have reduced the hypoglycemia risk. If the recommen-
dations made by both protocols are approximately the same, which in our experi-
ments is de¯ned as the di®erence being below a threshold of 10% of the historical
recommendation, then they can be considered equivalent.
By aggregating the outcomes of all historical data points of all patients evaluated
according to the principle above, one can estimate the overall performance of
the algorithm to be evaluated compared to that of the algorithm used to produce the
historical data. This aggregation of individual outcomes is referred to as the
\favorability" of the algorithm.
Table 2 de¯nes key symbols used in the favorability measurement. Algorithm 1
formalizes the favorability measurement for clarity. The algorithm depicts the steps
required to calculate the favorability of a protocol relative to the historical practice
at a single point in time t, with the protocol denoted by a vector . This algorithm is
essentially the same approach as described by Wong et al.3 but presented as pseudo
code. In order to calculate the overall relative favorability of a protocol based on all
available historical data, the algorithm needs to be applied to every consecutive
point in time for every patient in the historical data and the outputs need to be
summed.
Fig. 5. (Color online) Example visualization of an insulin infusion session for a patient. Red horizontal
lines indicate bounds for the normal range.







































































































Algorithm 1 is consistent with the framework published by Wong et al.3 However,
it should be pointed out that the algorithm may have potential caveats, which are
listed in what follows.
First of all, the algorithm treats the cases where the next blood glucose level is in
range or below range essentially in the same way (i.e. when the next blood glucose
measurement is on target or below target, the protocol recommending the lower
Table 2. De¯nitions of terms and symbols used in the favorability measurement. Note that while time
index t is shown explicitly, most of these terms can also be indexed by patient.
Term De¯nition
¯ ¼ ½0; . . . n1 numeric vector de¯ning the strategy being optimized (n ¼ 4 or n ¼ 8 depending on
the strategy)
t time
bgt historical blood glucose level at time t
It historical insulin infusion rate at time t
I t infusion rate change suggested by the strategy being tested at time t
I t recommended insulin infusion rate change at time t
 threshold for determining whether two insulin rate adjustments are equal, set to 0.1
(10%) in this paper
rhypo threshold for hypoglycemia, set to 6.0mmol/L
rhyper threshold for hyperglycemia, set to 8.0 or 10.0mmol/L
favtð¯Þ favorability at time t, de¯ned by Algorithm 1
 penalty size term for limiting magnitude of I t
obj(¯) the objective function to maximize during optimization
Algorithm 1. Function definition for computing relative favorability of a strategy
β at time t for a specific patient. Constants are defined in Table 2.
Function favt(β):
f ← case low(It, Iβt , bgt+1) +
case high(It, I
β





Function case low(It, I
β
t , bgt+1):
if bgt+1 < rhypo then





Function case high(It, I
β
t , bgt+1):
if bgt+1 > rhyper then





Function case target(It, I
β
t , bgt+1):
if bgt+1 ≥ rhypo & bgt+1 ≤ rhyper
then












































































































insulin infusion rate is considered more favorable). This is a potential weakness as the
in-range and below-range cases are not di®erentiated, implying that only the upper
bound of the target range (rhyper) is signi¯cant in the favorability calculation, and the
lower bound of the target range (rhypo) serves no practical purpose. It can be argued,
however, that a justi¯able ¯x is hard to ¯nd. In clinical scenarios where hospital in-
patients receive intravenous insulin infusion treatment, the risk of hypoglycemia
from insulin over-dosing is much more signi¯cant and threatening to the patient than
the risk of hyperglycemia from insulin under-dosing. Therefore, when the patient's
blood glucose level is in range, clinicians should almost always prioritize avoiding
insulin over-dosing rather than insulin under-dosing.
Second, the favorability of the algorithm to be evaluated is most likely an over-
estimate. When the blood glucose level is out of range, the favorability measurement
in itself cannot di®erentiate between a reasonable infusion rate change that returns
the blood glucose levels back to normal (indeed favorable) and an extreme change
that reduces blood glucose levels too much (in fact not favorable), and it will label
both as favorable. For the favorability evaluation, there is an implicit assumption
that all protocols being compared will recommend reasonable insulin doses at all
time  however, this is not necessarily the case in our situation where we are
starting our optimization from random protocols. To address and correct this issue, a
novel regularization or penalty term is added to the optimization process, which
leverages the connection between overestimations and extreme insulin rate changes.
This is a contribution of our research to the favorability evaluation framework, as it
introduces a way to gauge the overestimation in the favorability metric, and how to
penalize it, which will be further elaborated in the following sections.
4.2. Strategies
The novel methodology utilized in our research is to generalize the GRIP formula in
order to optimize it. The objective to be optimized is the relative favorability of the
current protocol (i.e. generalized GRIP) compared with the historical practice (i.e.
Waikato DHB protocol) on historical data (i.e. the processed dataset of 16 hospital
in-patients), as described in Sec. 4.1.
For experimental comparison purposes, two baseline strategies are included, i.e. A
and B. Strategy A, shown in Eq. (2), serves conceptually as the \No Change"
baseline, and proposes no change to the current insulin infusion rate. In other words,
the insulin infusion rate recommendation at a time point is the same as the historical
insulin infusion rate at the previous time point, i.e. the previous insulin infusion rate
decision. Although Strategy A is expected to perform poorly and be impractical, it is
included as a \sanity check" for the other strategies.
I ¼ 0: ð2Þ
The second baseline method, Strategy B, is the standard GRIP formula shown in
Eq. (1). GRIP takes a single blood glucose target value instead of a blood glucose







































































































range, i.e. Gtarget in Eq. (1). Originally, GRIP has a target value of 6.5mmol/L which
can be reasonably translated into a target range of 4–7.5mmol/L. In addition to the
original 6.5mmol/L target value, a target value of 8mmol/L is evaluated in Strategy
B as well, as this target value is intended to represent the 6–10mmol/L range, which
is the target range of the local DHB practice and the favorability measurement of our
research.
Next, two generalizations of the GRIP formula with optimizable parameters are
de¯ned. First of these, Strategy C replaces the constants in the original GRIP for-
mula with variables to be optimized. The strategy is de¯ned by Eq. (3). Strategy C
contains four tunable parameters, each corresponding to a constant in the original
GRIP protocol. To obtain the original GRIP formula, the four variables simply need
to be assigned as follows: 0 ¼ 1; 1 ¼ 0:25; 2 ¼ 0:2; 3 ¼ 0:3.
I¯ ¼ ð0 þ 1  I4 hÞ  ð2ðG0 GtargetÞ þ 3 4 hGÞ: ð3Þ
Since Strategy C is relatively low-dimensional with only four  values to optimize,
Strategy D is proposed, which is higher-dimensional, with greater °exibility in
modeling insulin infusion rate recommendation protocols, and represents a larger
space of potential protocols. Strategy D is de¯ned by Eq. (4).
I¯ ¼ 0 þ 1  I4 h þ 2  ðG0 GtargetÞ þ 3 4 hG
þ 4  I4 h  ðG0 GtargetÞ þ 5  I4 h 4 hG
þ 6  ðG0 GtargetÞ 4 hG
þ 7 4 hG ðG0 GtargetÞ  I4 h : ð4Þ
Essentially, Strategy D assigns an optimizable parameter as a coe±cient to each
of the input arguments of the original GRIP formula (i.e. I4 h , G0 Gtarget and
4 hG) and all their interactions (e.g. 4 hG I4 h). A tunable bias is also included
as 0. Therefore, Strategy D has a total of eight tunable parameters. To obtain the
original GRIP formula, the eight variables simply need to be assigned as follows:
0 ¼ 0; 1 ¼ 0; 2 ¼ 0:2; 3 ¼ 0:3; 4 ¼ 0; 5 ¼ 0:075; 6 ¼ 0:05; 7 ¼ 0.
It should be noted that G0 and Gtarget are grouped together to represent the error
between the current blood glucose levels and the target value. In practice, the target
value is selected by a clinician according to the patient's physical condition, and is
¯xed during each insulin infusion therapy session, i.e.Gtarget is a constant during each
session. Therefore, it makes sense to keep G0 and Gtarget as one term when expanding
the original GRIP formula into Strategy D, as doing so reduces the number of
optimizable parameters without sacri¯cing any modeling capacity of the strategy.
Additionally, the optimization process can always adjust the  values to ¯t the
training data regardless of the value of Gtarget, and the signi¯cance of Gtarget is in
providing clinicians with an adjustable target value/range for each insulin therapy
session.







































































































4.3. Approach to optimising the strategies
Based on the description of the metaheuristic search algorithms in Sec. 2.2, this
section provides further details on the individuals in the population and the ¯tness
function in the context of our research.
Although PSO and CMA-ES are di®erent algorithms, the list of optimizable
parameters can be implemented in the same straightforward fashion in both as a
vector that represents the space of potential solutions. For Strategy C, an individual
is a vector containing 0 to 3, which conforms with the four-dimensional search
space of Strategy C, and each individual contains its own 0 to 3 values that get
improved during the optimization process. It is the same with Strategy D, but with
0 to 7 representing the eight-dimensional search space of the strategy.
The objective function, whose return value is to be maximized for optimization,
calculates the overall ¯tness of an individual. An individual's recommended insulin
infusion rate change at each time point can be calculated from the the strategy's
formula with the ¯ vector of the individual, and the I4 h , G0 Gtarget and 4 hG
values in the historical data. Then the individual's recommended insulin infusion
rate at each time point can be calculated by adding its recommended change and the
historical insulin infusion rate at the previous time point. Finally, the individual's
favorability at each time point is determined by comparing its recommended insulin
infusion rate against the historical rate in the context of the blood glucose level at the
next time point (i.e. high glucose levels favor higher insulin infusion rates and low
glucose levels favor lower insulin infusion rates, refer also to Algorithm 1). The
overall favorability score of a potential protocol is the sum of the protocol's ¯tness
values at all the time points of all the patients' insulin infusion therapy sessions. As
explained in Sec. 4.1, a higher overall favorability score indicates better performance
of a protocol. Therefore, better con¯gurations for Strategy C or D can be found by a
continuous optimization algorithm by trying to maximize its population's ¯tness
scores. It should be pointed out that for each session the ¯rst and last time points
should be discarded for favorability evaluation because the ¯rst time point lacks a
previous historical insulin infusion rate and the last time point lacks a next blood
glucose measurement.
The favorability score alone is inadequate in representing a reasonable ¯tness
function, however. The favorability score has a tendency to increase the absolute
value of a protocol's recommended insulin infusion rate change. The reason is
speculated to be that, under the sole optimization pressure from the favorability
measurement, the continuous optimization process can only improve recommenda-
tions that are unfavorable, with no idea of how to improve favorable recommenda-
tions, some of which may be excessive and not truly bene¯cial. This phenomenon is
analogous to over-¯tting in Neural Networks, where the system satis¯es the evalu-
ation metric (e.g. the favorability metric) at the expense of practicality (e.g. being a
reasonable and useful protocol). As discussed in Sec. 4.1, the strong positive corre-
lation between the absolute value of a recommended change and the risk of







































































































overestimation calls for a penalty term to mitigate this e®ect. It is deemed appro-
priate to use, as a penalty term, the sum of the squared values of the insulin infusion
rate recommendations, i.e. at each time point a protocol is not only rewarded
according to its favorability, but also penalized according to the magnitude of its
recommended change. The penalty term is scaled by a user-speci¯ed parameter, as a
smaller multiplier emphasizes the favorability metric while a larger multiplier focuses
more on the penalty term, with the former encouraging more aggressive favorable
recommendations and the latter encouraging more moderate recommendations. The
good \middle ground" of this trade-o® needs to be determined by the user by
specifying an e®ective penalty scale, in order to produce a protocol which makes
favorable recommendations with as little excess as possible.
The return value of the ¯tness function is the overall favorability score, minus the












The equation shows that, given a protocol parameterized with a vector of tunable
variables ¯, the function sums over all the time points of all the patients. The
weighting of the penalty term is determined by a user-speci¯ed parameter .
4.4. Post-optimization veri¯cation
The resulting protocols obtained from the continuous optimization process can be
validated with Simglucose. Simglucose provides a good framework for evaluating
di®erent insulin administration protocols, and with some modi¯cations can perform
reasonably good simulations of intravenous insulin infusion therapy, as described in
Sec. 2.3. Simglucose performs its simulations using virtual patients, whose data have
never been exposed to the continuous optimization process. This is a key point to the
reliability of the validation outcome as all the protocols evaluated are equally blind
to the blood glucose behaviors of the simulated virtual patients.
Ten virtual adult patients with Type 1 Diabetes in the Simglucose implementa-
tion are used in the simulated validation and each simulation represents 240 h of
intravenous insulin therapy (i.e. 10 days of continuous insulin infusion). Among the
30 virtual patients, 10 adults are closest to the 16 real patients in the dataset in terms
of physical condition, while 10 adolescents deviate from the dataset in physical
condition such as body weight and insulin sensitivity and 10 children deviate even
further. The 10 virtual adults are the most similar to the intended recipients of the
protocols, and therefore used in our validation process. The total number of runs is
100 as 10 runs are performed on each patient.
Simglucose simulates carbohydrate intakes (i.e. meals), ultimately these are in-
cluded in the simulations, which means the virtual patients consume food as a Type 1
Diabetes patient would during their 10-day insulin therapy sessions. The decision
was made because simulations without meals turn out to be unchallenging and any







































































































reasonable protocol can stabilize the patients' blood glucose levels with utter ease.
Another reason is that meals introduce more randomness into the simulations as
blood glucose reading errors contain very limited randomness.
Three straightforward insulin bolus strategies are used in the simulations to assist
the infusion protocols in order to measure the performance of the protocols as well as
the bolus strategies. The three bolus strategies are as follows:
. No bolus whatsoever, relying entirely on the insulin infusion process for blood
glucose regulation after eating.
. Each time the patient consumes n grams of carbohydrate, the patient will be given
n
10 units of insulin bolus directly into the bloodstream in 15 min, which is the
current local DHB practice in insulin therapy for hospital in-patients.
. Each time the patient consumes n grams of carbohydrate, the patient will be given
n
5 units of insulin bolus directly into the bloodstream in 15 min, which is a more
proactive approach in avoiding after-meal hyperglycemia. This strategy is sug-
gested for investigation by the local DHB Diabetes expert, as mild after-meal
hyperglycemia is often observed among the hospital in-patients undergoing insulin
therapy using the current bolus strategy.
Rules are obtained from a Diabetes expert at the Waikato DHB to distinguish an
acceptable simulation run from an unacceptable one. All these rules must be satis¯ed
for a simulation run to be acceptable:
(1) Normoglycemia (4–10mmol/L inclusive) must be maintained for at least 50% of
the time in an insulin therapy session
(2) Signi¯cant hyperglycemia (over 14mmol/L) must not occur for more than 10%
of the time in an insulin therapy session
(3) Hypoglycemia (Below 4mmol/L) must not occur for more than 1% of the time in
an insulin therapy session
5. Results
The experimental results are covered here.
5.1. Optimization experiment results
This subsection analyzes the results of the optimization experiments.
5.1.1. Result overview
The entire 16-patient dataset contains 430 data points suitable for the favorability
measurement, excluding the ¯rst and last time points of each patient as described in
Sec. 4.3. Therefore, the theoretical maximum favorability that can be achieved by a
protocol is 430, which means that such a protocol would be more favorable than the
Waikato DHB protocol at every available time point in the dataset.







































































































Strategy A is evaluated to have an overall favorability of 90, which is very poor
and fully anticipated, as Strategy A is included as a baseline algorithm analogous to
the no-change algorithm.
Strategy B is evaluated with two di®erent target values, 6.5mmol/L for a target
range of 4–7.5mmol/L and 8mmol/L for a target range of 6–10mmol/L. Strategy B
with 6.5 mmol/L has a favorability of 202, while Strategy B with 8mmol/L has a
favorability of 215. Note that here Strategy B refers to the GRIP formula (Eq. (1))
but does not include any further constraints involved in real life scenarios where
GRIP is utilized. Indeed, these further constraints should be considered post-pro-
cessing, a great portion of which varies from hospital to hospital, as well as from
patient to patient. Given the task of optimising the GRIP formula (Strategy C and
Strategy D), it is best to evaluate the GRIP formula solely as a benchmark protocol.
The continuous optimization experiment results of Strategy C and Strategy D are
shown in Tables 3–6, also visualized in Figs. 6–9. During each experiment, the
population is optimized for 100 iterations. For either Strategy C or D, 36 con¯g-
urations are explored, involving the PSO and CMA-ES algorithms, population
sizes of 80, 160 and 320, as well as penalty scale  values of 106, 105, 104, 103,
102 and 101 (i.e. 2ðalgorithmsÞ  3ðpopulation sizesÞ  6ðpenalty scalesÞ ¼
36ðconfigurationsÞ). Each con¯guration is evaluated through 10 runs, each of which
produces a potential protocol at the end of the continuous optimization process, and
Tables 3–6 show the statistics of the 10 runs, i.e. the best and median values of the
favorability measurement and the penalty term before scaling.
The tables indicate that Strategy D clearly outperforms Strategy C, as Strategy D
achieves signi¯cantly greater favorability, compared with Strategy C given the same
con¯guration, without the penalty growing signi¯cantly. The greatest favorability
achieved by Strategy D is 309 while Strategy C achieved a maximum of 280.
Table 3. Favorability results for strategy C.
Best fav

(Median fav) 106 105 104 103 102 101
PSO 80 279 277 271 262 229 184
(278) (276) (271) (259) (223) (175.5)
160 279 277 272 264 231 185
(278) (275.5) (271) (262.5) (223.5) (177)
320 279 277 274 264 233 184
(279) (276.5) (271) (261.5) (226.5) (179)
CMA-ES 80 280 277 271 260 228 180
(278.5) (276.5) (271) (260) (227.5) (180)
160 279 277 271 260 233 180
(279) (277) (271) (260) (228) (180)
320 280 277 271 260 231 180
(279) (277) (271) (260) (226) (180)







































































































Focusing on Table 5, i.e. the favorability results of Strategy D, it can be seen that
CMA-ES consistently outperforms PSO, except when the penalty scale  is relatively
large and arguably the favorability score becomes less than desirable. On the grounds
that PSO may require more iterations to achieve the same level of performance as
CMA-ES, the Strategy D experiments with the PSO con¯gurations are re-run with
1,000 iterations instead of the original 100. However, no signi¯cant improvement is
observed of the 1,000-iteration results. Therefore, it can be concluded that CMA-ES
is the superior metaheuristic search algorithm for this speci¯c problem.
By examining Tables 4 and 6, it can be seen that the negative correlation between
the penalty scale  and the unscaled penalty sum is clear. For example, focusing on
the CMA-ES results of Strategy D, a small  value such as 106 leads to very large
Table 4. Penalty sum results for strategy C.
Min sum

(Median sum) 106 105 104 103 102 101
PSO 80 7.4e5 1.2e5 3.3e4 9.3e3 1.7e3 1.8e2
(8.3e5) (2.6e5) (6.4e4) (1.2e4) (2.1e3) (2.6e2)
160 3.0e5 1.1e5 3.2e4 1.1e4 1.7e3 2.1e2
(7.9e5) (1.7e5) (6.4e4) (1.5e4) (2.0e3) (2.7e2)
320 3.6e5 1.2e5 4.3e4 9.6e3 1.7e3 2.3e2
(7.8e5) (2.6e5) (6.0e4) (1.4e4) (2.3e3) (2.8e2)
CMA-ES 80 7.0e5 1.2e5 5.6e4 1.1e4 2.0e3 2.5e2
(1.2e6) (2.4e5) (5.6e4) (1.1e4) (2.3e3) (2.5e2)
160 7.0e5 1.9e5 5.6e4 1.1e4 1.9e3 2.5e2
(7.3e5) (2.5e5) (5.6e4) (1.1e4) (2.3e3) (2.5e2)
320 7.0e5 1.1e5 5.6e4 1.1e4 1.9e3 2.5e2
(7.6e5) (2.5e5) (5.6e4) (1.1e4) (2.1e3) (2.5e2)
Table 5. Favorability results for strategy D.
Best fav

(Median fav) 106 105 104 103 102 101
PSO 80 303 298 290 275 253 219
(300) (294.5) (282.5) (258) (209) (156.5)
160 302 300 300 286 264 192
(299.5) (297) (286.5) (268) (203) (156.5)
320 305 301 293 277 263 191
(302) (297) (290.5) (264) (229) (162.5)
CMA-ES 80 309 305 304 290 248 202
(309) (305) (304) (287.5) (243) (194)
160 309 306 305 290 248 200
(309) (305) (304) (290) (248) (194)
320 309 306 304 290 248 202
(309) (305) (301) (290) (248) (200.5)







































































































Fig. 6. Strategy C favorability results.
Fig. 7. Strategy C penalty results.
Table 6. Penalty sum results for strategy D.
Min sum

(Median sum) 106 105 104 103 102 101
PSO 80 3.5e5 1.9e5 4.5e4 6.3e3 4.6e3 1.2e3
(9.3e5) (3.1e5) (9.9e4) (3.2e4) (8.9e3) (4.3e3)
160 3.4e5 2.0e5 4.2e4 1.7e4 1.7e3 1.0e3
(6.4e5) (3.8e5) (8.7e4) (2.4e4) (6.6e3) (4.0e3)
320 3.4e5 1.7e5 3.2e4 1.2e4 3.3e3 8.8e2
(1.0e6) (2.5e5) (1.0e5) (2.2e4) (7.5e3) (4.4e3)
CMA-ES 80 1.3e6 2.3e5 7.0e4 9.3e3 1.7e3 1.9e2
(1.5e6) (2.7e5) (7.7e4) (1.2e4) (2.1e3) (2.1e2)
160 1.5e6 1.2e5 6.5e4 1.2e4 2.0e3 1.8e2
(1.5e6) (2.4e5) (7.6e4) (1.2e4) (2.4e3) (2.1e2)
320 1.5e6 1.2e5 6.5e4 1.2e4 2.4e3 1.8e2
(1.5e6) (2.3e5) (7.1e4) (1.2e4) (2.4e3) (2.2e2)







































































































unscaled penalty sums like 1:5 106, which indicates that the recommended insulin
infusion rate changes I are likely to be very large in its absolute value, giving the
protocol a high favorability score on paper but making it potentially impractical. On
the other hand, a large  value such as 0:1 leads to small unscaled penalty sums like
1:8 102, which suggests that the recommended insulin infusion rate changesI are
likely to be small, however, the favorability score may reach merely 200 in these
con¯gurations, making the optimization result even slightly less favorable than the
original GRIP formula (which achieved a favorability score of 202 or 215 depending
on the selected target value).
It can therefore be pointed out that the selection of a single optimal protocol
requires a reasonable trade-o® between the total favorability score and the penalty
sum. As discussed above, extreme  values, large or small, do not produce optimal
protocols. Examining Strategy D and using Tables 5 and 6, it can be seen that the
favorability decreases relatively slowly for  values from 106 to 103 while the
Fig. 9. Strategy D penalty results.
Fig. 8. Strategy D favorability results.







































































































penalty sum decreases signi¯cantly in the same range. However, a drastic drop in
favorability begins at  ¼ 0:01 and making results in this range far less desirable than
the previous range. It can therefore be argued that the  value of 103 is the optimal
amongst the six  values.
It can be noted in addition that CMA-ES is relatively robust in terms of its
population size, as no clear performance gain or loss in terms of favorability or
penalty is observed relative to the population size in the CMA-ES experiments. It
can therefore be speculated that all nontrivial population sizes produce similar
results with CMA-ES, as the performance saturation in terms of population size can
be attributed to the optimum in the search space already being su±ciently explored,
therefore increasing the population size further does not grant improved
performance.
5.1.2. Protocol analysis
One resulting protocol, which is deemed optimal of the experimental output, is given
for further examination. The protocol comes from the following con¯guration:
. Strategy D,
. CMA-ES as the metaheuristic search algorithm,
. Population size of 320 and
. Penalty scale  value of 103.
Referring to Eq. (4), which is the formula for Strategy D, the exact values of the
tunable parameters are shown in Table 7. The assignment of these variables results
in a novel protocol shown in Eq. (6).
I¯ ¼ 4:140þ 0:354 I4 h þ 1:600 ðG0 GtargetÞ þ 0:141
4 hG 0:059 I4 h  ðG0 GtargetÞ  0:034 I4 h
4 hG 0:027 ðG0 GtargetÞ 4 hGþ 0:009
4 hG ðG0 GtargetÞ  I4 h : ð6Þ
Table 8 shows the protocol's recommendations for nine representative examples
from the data. From this table, we can see that most of the recommendations seem

















































































































reasonable. For example, in Case 1, where blood glucose levels are initially well above
the 8 mmol/L target but decreasing over the past four-hour period, moderate
increases in insulin rate are recommended. Case 2, on the other hand, represents a
patient who is already below target but has been receiving some insulin over the past
four hours. In this case, moderate negative adjustments are recommended. Case 4
shows a patient with high initial glucose levels that have not changed much in the
past four hours, and therefore signi¯cant increments in insulin pump rate are
recommended. Finally, Case 9 shows a patient at signi¯cant risk of severe hypo-
glycemia following a signi¯cant drops in glucose level. In this case, a large negative
adjustment is recommended which e®ectively sets the insulin pump rate to zero
(since negative pump rates do not make sense). The remaining cases show similar
sensible recommendations being made.
Figure 10 is a visualization of the same strategy used to produce the recom-
mendations in Table 8. To produce the visualization, we ¯xed values of I4 h and
4 hG to di®erent constants and plotted the resulting linear relationships betweenG0
and I. Note that the model itself is not linear in practice, since I4 h and 4 hG
would be constantly changing over time. The true model is a curved surface in four
dimensions, nonetheless, this type of visualization enables us to see some of the
model's properties.
The I4 h and 4 hG inputs both appear to in°uence the slope of the G0=I
relationship. In particular, negative values of 4 hG (indicating a decrease in blood
glucose levels over the past four hours) and large values of I4 h (indicating high
insulin infusion rates over the past four hours) result in a gentler slope and therefore
smaller rate increments when an increase is recommended. The ¯gure shows that
when I4 h is set to 5.0, the protocol recommends no change when G0 is approxi-
mately 8.0, regardless of 4 hG. This indicates that the protocol considers the sce-
nario where the blood glucose level is around 8.0 mmol/L and the average infusion
rate has been around 5.0 U/h to be a relatively stable state, and recommends keeping
the same insulin infusion rate until there are further glucose changes. For the plot, we
Table 8. Sample recommendations from
the dataset.
Case I4 h G0 4hG Rec. I¯
1 3.7 11.8 8.8 4.1
2 4.3 6.3 2.1 2.8
3 8.2 15.0 6.2 6.7
4 5.3 13.7 0.2 7.0
5 3.0 9.9 2.8 1.9
6 1.6 12.4 3.0 5.3
7 8.5 14.7 0.9 8.1
8 2.0 11.8 1.4 4.5
9 3.5 4.2 4.4 6.2







































































































selected4 hG values of 5.0 and 5.0, since they are \typical" values for this variable
in the data, while 20.0 and 15.0 are rare extreme values.
5.2. Veri¯cation experiment results
Table 9 summarizes the simulation results. It should be noted that both GRIP and
Strategy D are given a target of 8mmol/L, as well as GRIP's practical constraints,
i.e. I  1:5mmol/L and I  10mmol/L.
The Strategy D protocol achieved competitive results. It can be reasoned that to
make a good formula-based protocol, both a good formula and reasonable engi-
neering are necessary. However, an intriguing ¯nd is that when the formula was
developed it was blind to the engineered features that would be added later (i.e. in
the continuous optimization phase Strategy D was a pure formula without any
manually de¯ned constraints), yet it achieves top-level performance with common-
sense constraints. This ¯nding supports the viability of this metaheuristic approach,
where interpretable models are developed through optimization and only modest
Table 9. Number of acceptable runs achieved by each in-
fusion protocol.
DHB Sigmoid GRIP Strategy D
Standard bolus 46 29 2 54
Double bolus 31 21 10 51
No bolus 10 0 2 2
Fig. 10. Visualization of one optimized version of strategy D.







































































































engineering is required to modify the models to make them suitable for problems in
speci¯c domains.
The table also shows that the protocols perform signi¯cantly worse without in-
sulin boluses. Therefore, it is reasonable to say that in scenarios where the patient
consumes carbohydrate, either insulin boluses are required or e®orts need to go into
making the continuous insulin infusion protocol handle carbohydrate intakes ex-
plicitly (i.e. increasing the insulin infusion rate according to the amount of food
consumed), because trying to use the protocol to implicitly handle food intake (i.e.
waiting for the protocol to recommend more insulin after the blood glucose level has
already risen) tends to lead to more glucose °uctuations both above and below range,
and ultimately leads to ine®ective glucose control.
The protocols also tend to perform a bit better with the standard bolus scheme
currently employed at the local DHB compared with the double-bolus scheme. It is
speculated that a plain double-bolus scheme increases hypoglycemia risk in some
patients who might have a higher insulin sensitivity. It remains to be seen if a
potentially more complex bolus scheme, e.g. a scheme that recommends di®erent
amounts of bolus insulin for patients in di®erent health conditions, can lead to
signi¯cantly better glucose control.
6. Conclusion
Our research utilizes metaheuristic search algorithms to optimize GRIP with respect
to historical data recorded by the local DHB, and the resulting protocols are vali-
dated with Simglucose and show superior performance when compared with GRIP
and the local DHB protocol. In the end, the strategy D models are fairly optimized
and extended to have become very di®erent from the original GRIP formula, which is
the starting point of its optimization.
Our research demonstrates the usefulness of Arti¯cial Intelligence techniques that
produce interpretable models. Such interpretable models can be understood and
reasoned, and this is very important in domains where the behavior of software and
tools need to be fully known, e.g. medical informatics. The interpretability also
makes new ways of manipulating the model easier. Therefore, interpretable models
combine nicely with elegant engineering, which makes it easy to do quick prototyping
with such models.
The combination of the metaheuristic search algorithms and the favorability
evaluation framework prove to work well and produce results of value, which is
further veri¯ed by the simulations facilitated by Simglucose. The overall paradigm of
optimizing on historical data and validating with simulations (or potentially the
other way round, optimizing on simulations and validating with historical data)
turns out to be e±cient and robust for research endeavors. In this paradigm, only one
real-world dataset is required, and concerns over the overlap between optimization
and validation data should be minimum, as the two processes utilize data from very







































































































di®erent sources (with the real-world data being more statistical and the simulations
being more theoretical).
Outstanding Strategy D protocols are found through simulated validation, and it
is recommended that these protocols be further examined by medical experts in the
diabetes ¯eld. If these examinations return positive results, further engineering on
these protocols through collaborations between medical and computer science
experts may produce optimal insulin rate protocols appropriate for clinical trials.
For future work, there are other optimization techniques that can be applied to
our research problem, such as Genetic Programming,17 Neural Networks that pro-
duce interpretable models,18 etc. It is also an interesting idea to try to improve the
strategy's response to meals, as GRIP does not take meals into account likely due to
it being developed with ICU settings in mind. More explicit questions would be what
formula to use for the protocol's response to meals and what kind of dataset is needed
in order to optimize such a formula. The favorability framework's response to nor-
moglycemia could also be improved, as currently it responds to normoglycemia in the
same way as it does to hypoglycemia.
In addition, there are other protocols that may serve as good starting points like
GRIP in this paradigm. Examples include PID-based controllers,19 mathematical-
function-based strategies like the sigmoidal protocol,8 and instruction-and-table-
based protocols such as the one used at the Waikato DHB.
Lastly, our research produces protocols that suggest insulin infusion rate changes
but not the initial insulin infusion rate when a therapy session starts. Simple
guidelines included in the current local DHB practice should su±ce in providing an
initial rate. It is nearly impossible for any protocol to come up with a perfect initial
rate due to the great uncertainty involved at the start of a session. For a protocol,
correctly adjusting the infusion rate as a session continues is far more important
and feasible than merely coming up with a perfect rate initially, as long as its
initial recommendations are reasonable. Nevertheless, it remains an interesting
topic to discover strategies that could give better starts to insulin infusion therapy
sessions.
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